Atypical antipsychotics in the treatment of early-onset schizophrenia

Michal Hrdlicka, Iva Dudova Department of Child Psychiatry, Charles University Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic Abstract: Atypical antipsychotics (AAPs) have been successfully used in early-onset schizophrenia (EOS). This review summarizes the rando...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hrdlicka M, Dudova I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/06b0293d55704c5dbf7922a4eb60d14f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:06b0293d55704c5dbf7922a4eb60d14f
record_format	dspace
spelling	oai:doaj.org-article:06b0293d55704c5dbf7922a4eb60d14f2021-12-02T06:08:27ZAtypical antipsychotics in the treatment of early-onset schizophrenia1178-2021https://doaj.org/article/06b0293d55704c5dbf7922a4eb60d14f2015-04-01T00:00:00Zhttp://www.dovepress.com/atypical-antipsychotics-in-the-treatment-of-early-onset-schizophrenia-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Michal Hrdlicka, Iva Dudova Department of Child Psychiatry, Charles University Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic Abstract: Atypical antipsychotics (AAPs) have been successfully used in early-onset schizophrenia (EOS). This review summarizes the randomized, double-blind, controlled studies of AAPs in EOS, including clozapine, risperidone, olanzapine, aripiprazole, paliperidone, quetiapine, and ziprasidone. No significant differences in efficacy between AAPs were found, with the exception of clozapine and ziprasidone. Clozapine demonstrated superior efficacy in treatment-resistant patients with EOS, whereas ziprasidone failed to demonstrate efficacy in the treatment of EOS. Our review also focuses on the onset of action and weight gain associated with AAPs. The data on onset of action of AAPs in pediatric psychiatry are scanty and inconsistent. Olanzapine appears to cause the most significant weight gain in patients with EOS, while ziprasidone and aripiprazole seem to cause the least. Keywords: early-onset schizophrenia, atypical antipsychotics, efficacy, onset of action, weight gainHrdlicka MDudova IDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 907-913 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Hrdlicka M Dudova I Atypical antipsychotics in the treatment of early-onset schizophrenia
description	Michal Hrdlicka, Iva Dudova Department of Child Psychiatry, Charles University Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic Abstract: Atypical antipsychotics (AAPs) have been successfully used in early-onset schizophrenia (EOS). This review summarizes the randomized, double-blind, controlled studies of AAPs in EOS, including clozapine, risperidone, olanzapine, aripiprazole, paliperidone, quetiapine, and ziprasidone. No significant differences in efficacy between AAPs were found, with the exception of clozapine and ziprasidone. Clozapine demonstrated superior efficacy in treatment-resistant patients with EOS, whereas ziprasidone failed to demonstrate efficacy in the treatment of EOS. Our review also focuses on the onset of action and weight gain associated with AAPs. The data on onset of action of AAPs in pediatric psychiatry are scanty and inconsistent. Olanzapine appears to cause the most significant weight gain in patients with EOS, while ziprasidone and aripiprazole seem to cause the least. Keywords: early-onset schizophrenia, atypical antipsychotics, efficacy, onset of action, weight gain
format	article
author	Hrdlicka M Dudova I
author_facet	Hrdlicka M Dudova I
author_sort	Hrdlicka M
title	Atypical antipsychotics in the treatment of early-onset schizophrenia
title_short	Atypical antipsychotics in the treatment of early-onset schizophrenia
title_full	Atypical antipsychotics in the treatment of early-onset schizophrenia
title_fullStr	Atypical antipsychotics in the treatment of early-onset schizophrenia
title_full_unstemmed	Atypical antipsychotics in the treatment of early-onset schizophrenia
title_sort	atypical antipsychotics in the treatment of early-onset schizophrenia
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/06b0293d55704c5dbf7922a4eb60d14f
work_keys_str_mv	AT hrdlickam atypicalantipsychoticsinthetreatmentofearlyonsetschizophrenia AT dudovai atypicalantipsychoticsinthetreatmentofearlyonsetschizophrenia
_version_	1718400033197391872

Atypical antipsychotics in the treatment of early-onset schizophrenia

Ejemplares similares